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Abstract
The survival of patients with multiple myeloma (MM) has significantly improved in recent years 
due to the introduction of new drugs such as proteasome inhibitors (PI) or immunomodulatory 
drugs (ImiDs). However, MM is still an incurable condition, with very variable clinical course. 
The group of patients with especially poor prognosis are individuals with relapsed/refractory multi-
ple myeloma (RRMM) with specific cytogenetic disorders — del(17p), t(4;14), t(14;16). Among the 
therapies that are currently in use the ixazomib–lenalidomid–dexamethasone (IRd) is considered 
as a candidate to improve outcome.
In this study, we analyzed the cases of patients diagnosed with high-risk molecular RRMM, who 
have been treated with the IRd chemotherapy regimen. An aggressive case report with no known 
cytogenetic data was also added. The data was collected from four centers in Poland as part of the 
Polish Myeloma Group observational study.
The results suggest high efficacy and good safety profile of IRd therapy in patients with RRMM and 
unfavorable cytogenetics.
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Introduction
Multiple myeloma (MM)/plasma cell myeloma 
(PCM) is a chronic, incurable neoplastic disease 
characterized by a clonal expansion of neoplastic 
plasma cells having the ability to produce pathologi-
cal monoclonal protein. Its clinical course is very 
diverse and estimated survival is from 2 to over 10 
years. Disease relapse is a common problem even 
after achieving complete remission. Any treat-
ment given, by destroying drug-sensitive clones, 
favours the selection of more aggressive clones 
with cumulative genetic aberrations. In cases of 
chemoresistance, the chances to achieve clinical 
response are relatively slim [1].
The most important factors having influence 
on the prognosis of MM patients include defined 
cytogenetic abnormalities. “High risk” aberrations 
detected routinely by fluorescence in situ hybridiza-
tion (FISH) include translocations t(4;14), t(14;16), 
t(14;20), deletion of chromosome 17p [del(17p)], 
hypodiploidy and 1q21 amplification [2–5].
Undoubtedly among the entire population of 
patients with MM — as a particularly unfavourable 
group prognostically — is a group with a resist-
ant/refractory form (RRMM, relapsed/refractory 
multiple myeloma) with unfavourable cytogenetic 
aberrations. The selection of appropriate therapy 
becomes the key for such patients. Treatment 
strategies that have become promising include 
a combination of a proteasome inhibitor (PI) with 
lenalidomide/pomalidomide, double autologous 
stem cell transplant or a combination of immuno-
therapy with the use of lenalidomide/pomalidomide 
[6]. Nevertheless, there is a need for additional 
active treatment options, including regimens that 
will allow long-term treatment and disease control. 
Among those new currently used options, hopes 
are put on triple-drug therapy regimen ixazomib– 
–lenalidomide–dexamethasone (IRd).
Ixazomib is the first oral PI which in combina-
tion with lenalidomide–dexamethasone (Rd) has 
been approved for the treatment of patients with 
MM after at least one previous line of treatment 
[7]. In the TOURMALINE-MM1 registration trial, 
ixazomib showed significant improvement in disease 
progression-free survival (PFS) (median PFS 20.6 vs. 
14.7 months) and a higher response rate, with limited 
additional toxicity. What is particularly interesting, 
thanks to this treatment, the results were equalled in 
patients with high and standard cytogenetic risk [8].
Ixazomib is currently available for patients in 
Poland within an early access program. The paper 
presents the first Polish clinical observations of 




A 73-year-old male with second relapsed multiple 
myeloma/lambda light chain disease and multiple 
cytogenetic aberrations (del17p, amp1q21)
In December 2016, a 68-year-old man was 
admitted to the medical ward of a district hospi-
tal due to increasing weakness and symptoms of 
worsening heart failure. Based on medical history 
he was diagnosed with gastric ulcer, diverticular 
disease and sigmoid polyp, permanent atrial fibril-
lation, hypertension. Within the last 3 months, the 
patient had been hospitalized due to embolus of 
the left popliteal artery and pneumonia of the left 
lung as well as Staphylococcus aureus sepsis. He 
was treated with an embolectomy and received 
intensive antibiotic therapy. The patient was on 
long term pantoprazole, telmisartan, enoxaparin, 
acetylsalicylic acid, clopidogrel, spironolactone 
and furosemide. He received iron supplementation 
parenterally due to iron deficiency anaemia in 2020.
Laboratory tests on admission showed mod-
erate macrocytic anaemia (haemoglobin concen-
tration [Hb] 9.3 g/dL, mean corpuscular volume 
[MCV] 95.0 fL), reduced iron concentration (Fe 
40.23 µg/dL), elevated ferritin (431.1 ng/mL) and 
high concentration of C-reactive protein ([CRP] 
98.9 mg/L). Based on the results of imaging tests 
performed, i.e., gastrointestinal endoscopy and 
computed tomography (CT) of thorax and abdomen 
no obvious cause of anaemia was found. Diagnostic 
bone marrow trephine biopsy was carried out.
The obtained trephine biopsy was reported as 
medium hypercellular (20–40% of marrow spaces), 
normal haematopoietic lineages were significantly re-
duced, abundant interstitial infiltrate with plasma cells 
(CD138+, immunoglobulin free light chains lambda+, 
kappa–) were comprising about 80% of all cells.
The patient was referred to the Department 
of Hematooncology and Bone Marrow Transplanta-
tion of the University Hospital in Lublin in order 
to complete diagnostics and treatment. Serum 
protein electrophoresis did not confirm monoclonal 
protein band but significantly increased concentra-
tion of lambda free light chains (FLC) in serum 
5095.37 mg/L was found with a concentration ratio 
of lambda/kappa chain of 622 mg/L. A CT scan of 
the skeleton revealed generalized osteoporosis 
of bone structures and the presence of multiple 
disseminated osteolytic lesions (the largest with 
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dimensions 18 × 13 mm) in the bones of the skull, 
cervical and thoracic spine, femurs, tibiae and 
fibulae. The diagnosis of MM/lambda light chain 
disease was established, stage II according to the 
Durie-Salmon scale, II according to the Interna-
tional Staging System (ISS).
The patient was qualified for first-line chemo-
therapy bortezomib–cyclophosphamide–dexa-
methasone (VCD). Treatment started in February 
2017 with standard doses: 1.3 mg/m2 bortezomib 
on days 1, 4, 8, and 11; 500 mg/m2 cyclophospha-
mide on days 1 and 8, 40 mg dexamethasone on 
days 1–4 and 8–11 of 28-day cycles. At the same 
time, supportive treatment with zolendronic acid 
was started as well as antibacterial and antiviral 
prophylaxis (sulfamethoxazole + trimethoprim, 
acyclovir). During treatment episodes of hyper-
glycaemia up to 300 mg/dL were observed, which 
necessitated the implementation of insulin therapy 
and reduction of dexamethasone dose to 12 mg on 
days 1–2, 4–5, 8–9 and 11–12. After 6 treatment 
cycles, very-good partial remission of the disease 
(VGPR) was reported, with a decrease in the con-
centration of lambda FLC in serum to 455.52 mg/ 
/L (approx. 91%). In August 2017, a diagnostic 
coronary angiography was performed, followed 
by right coronary artery angioplasty (PTCA RCA, 
percutaneous transluminal coronary right coronary 
artery angioplasty) with metal stent implantation 
(BMS, bare-metal stent). Because of comorbidities 
autologous haematopoietic stem cell transplanta-
tion (auto-HSCT) procedure was not performed. 
Given the infective complications (pharyngitis, 
pneumonia) and hypogammaglobulinaemia (IgG 
3.3 g/L, IgM 0.25 g/L, IgA 0.5 g/L), it was decided to 
end the treatment in October 2017 after completion 
of 7 cycles of chemotherapy, starting immunoglobu-
lin replacement therapy and close observation.
In January 2018, just after 3 months after the 
end of VCD chemotherapy, the patient developed 
disease progression (PD), increased concentra-
tion of lambda FLC up to 1036.61 mg/L. Second-
-line treatment was initiated according to thalido-
mide–dexamethasone (TD) protocol. Thalidomide 
100 mg/day and dexamethasone 12 mg on days 
1–4 of the 28-day treatment cycle were given. 
During chemotherapy, polyneuropathy to degree 
3 according to NCI CTCAE (National Cancer In-
stitute Common Terminology Criteria for Adverse 
Events) was observed. The treatment was stopped 
in December 2018, after completed 10 cycles, ob-
taining disease stabilization (SD, stable disease). 
Lambda FLC concentration lowered to 674.0 mg/L 
(approx. 35%).
In February 2018 an increase in lambda FLC 
concentration to 1204.6 mg/L was noted. The patient 
reported deterioration of his general condition, weak-
ness. In laboratory tests, again anaemia (Hb 10.5 g/ 
/dL) was observed. Given the aggressive course, 
short periods of disease remission, a decision was 
made to extend the diagnostics with a cytogenetic 
examination of the bone marrow. The patient was 
qualified for the next line of chemotherapy according 
to the lenalidomide–dexamethasone (Rd) regimen. 
Lenalidomide 25 mg/day and dexamethasone 20 mg 
were recommended on days 1–4, 8–11 and 15–18 
of 28-day cycles. FISH revealed complex molecular 
aberrations, TP53 deletion in 36% and CKS1B gene 
amplification (locus 1q21) in 100% of plasma cells 
examined. Due to this, a request for treatment with 
ixazomib within the early access program was made. 
Ixazomib was added to therapy from Rd treatment 
cycle 2 at the dose of 4 mg on days 1, 8 and 15. 
Subcutaneous administration of immunoglobulins 
was continued. During treatment, upper respiratory 
tract infection and grade 3 pneumonia were reported. 
The severity of peripheral polyneuropathy reduced 
to grade 1 in the lower limbs. From treatment cycle 
6, the lenalidomide dose was reduced to 15 mg/day. 
With the treatment administered, disease control at 
the SD level was achieved. The deepest response was 
noted after the 4th treatment cycle with lambda FLC 
concentration decrease to 614.52 mg/L (by around 
49%). The patient received a total of 12 treatment 
cycles. In May 2020, there was a progression with 
an increase in lambda FLC up to 1090.0 mg/L. The 
patient is undergoing another line of chemotherapy 
according to the pomalidomide–dexamethasone (Pd) 
protocol.
Case 2
A 73-year-old male with relapsed IgG kappa multiple 
myeloma (del17p)
In June 2017, a 72-year-old man with monoclo-
nal gammopathy was admitted to the Department 
of Haemato-Oncology and Bone Marrow Trans-
plantation in Lublin for further diagnostics. The 
patient reported weakness being present for the 
last few months, periodically night sweats and bone 
pain. About 5 months earlier, the patient had been 
hospitalized for right lung pneumonia on a medi-
cal ward of a district hospital. In laboratory tests 
he had been found then to have mild normocytic 
anaemia (Hb ~11.5 g/dL), ESR around 100 mm/h 
and presence of monoclonal IgG kappa protein in 
serum (M protein 3.06 g/dL in January 2017). The 
patient was treated for hypertension and chronic 
obstructive pulmonary disease (COPD).
11https://journals.viamedica.pl/hematology_in_clinical_practice
Marek Hus et al., Ixazomib in high-risk myeloma
In control laboratory tests anaemia was con-
firmed (Hb 11.3 g/dL), while calcium levels were 
noted to be normal (Ca 2.17 mmol/L) as well as 
creatinine (0.9 mg/dL). A distinct protein M peak 
was present on serum protein electrophoresis 
IgG kappa 3.79 g/dL, kappa FLC concentration 
was 52.06 mg/L, and kappa/lambda chain ratio — 
24.56. Bone marrow aspirate revealed an increased 
percentage of plasma cells expressing kappa light 
chains on immunophenotypic assessment — about 
20%. CT skeletal survey showed features of os-
teoporosis with disseminated osteolytic foci (the 
largest with a dimension of 20 mm) within the ver-
tebrae, right femur, left humerus and foot bones. 
Results of FISH examination showed TP53 gene 
deletion — 8%. Eventually, the diagnosis of MM 
IgG kappa stage III according to the Durie-Salmon 
scale and stage II ISS was made.
The patient was qualified for the first-line 
chemotherapy according to the bortezomib–tha-
lidomide–dexamethasone (VTD) protocol. The 
treatment commenced in July 2017. Bortezomib 
was given 1.3 mg/m2 on days 1, 4, 8, and 11; 
thalidomide 100 mg/day, dexamethasone 20 mg 
on days 1–4 and 8–11 of 28-day treatment cycles. 
Thromboprophylaxis was recommended [subcuta-
neous (s.c.) enoxaparin], antiviral (acyclovir), anti-
bacterial (sulfamethoxazole + trimethoprim) and 
supportive treatment with disodium pamidronate. 
During treatment, grade 3 neutropenia, constipa-
tion, peripheral oedema and peripheral polyneu-
ropathy were periodically observed. Symptomatic 
drugs were given, and it was decided to reduce the 
dose of dexamethasone to 10 mg on days 1–4 and 
8–11 from cycle 4. The treatment was stopped after 
5 cycles due to polyneuropathy NCI CTCAE grade 
3, achieving partial remission (PR) with reduction 
of M protein concentration to 0.49 g/dL (approx. 
87%). The patient did not qualify for auto-HSCT 
due to advanced age and co-morbidities.
In October 2018, the patient developed PD 
with IgG kappa M protein increase to 1.09 g/dL. 
In control routine laboratory tests, no significant 
abnormalities were observed. The patient did not 
report any symptoms. Signs of polyneuropathy 
subsided; they were assessed as grade 1 in the 
lower limbs. The patient was qualified for the 
second-line chemotherapy according to IRd. Ad-
ministered doses: 4 mg of ixazomib on days 1, 8 and 
15, 25 mg of lenalidomide on days 1–21, 20 mg 
of dexamethasone on days 1, 8, 15 and 22. Throm-
boprophylaxis was continued as well as antiviral 
and antibacterial prophylaxis and treatment with 
disodium pamidronate. The treatment was toler-
ated very well. The patient has received so far 12 
chemotherapy cycles. From cycle 8 of IRd, a very 
good clinical response (VGPR) has been sustained, 
in serum protein electrophoresis oligoclonal pro-
file, FLC normal. So far, no complications of the 
treatment have been observed.
Case 3
A 72-year-old woman with relapsed multiple  
myeloma/lambda light chain disease (del17p)  
with severe renal failure
In June 2017, a 70-year-old female patient 
with multiple co-morbidities was admitted to the 
Department of Hematooncology and Bone Marrow 
Transplantation of the University Hospital in Lublin 
in average general condition [Eastern Cooperative 
Oncology Group (ECOG) performance status 3] 
for further diagnostics, with profound anaemia (Hb 
~7.0 g/dL) requiring transfusion of red blood cell 
concentrate (RBCC), severe chronic renal impair-
ment (estimated glomerular filtration rate [eGFR] 
~15 mL/min), proteinuria.
Six months earlier, the patient developed 
myocardial infarction after angioplasty of the left 
anterior descending coronary artery (PCI LAD, 
percutaneous coronary intervention (left anterior 
descending)) with drug-eluting stent (DES) implan-
tation with an anti-proliferative effect complicated 
by arrhythmias with ventricular fibrillation and 
sudden cardiac arrest. Within the last 3 months 
significant weakness and weight loss approximately 
15 kg. In the control laboratory tests, a gradual 
deterioration of kidney functional parameters 
was observed (creatinine ~5 mg/dL, eGFR ~10– 
–15 mL/min), proteinuria and anaemia, ESR up to 
120 mm/h.
Serum protein electrophoresis did not confirm 
monoclonal protein, but a significantly increased 
concentration of lambda FLC — 5529.43 mg/L 
was noted with a lambda/kappa ratio of around 
265. Bone marrow aspirate showed an increased 
percentage of plasma cells expressing lambda 
light chains by immunophenotyping — about 38%. 
FISH examination revealed TP53 gene deletion 
— 100%. CT skeletal survey showed features of 
osteoporosis with single osteolytic lesions. The 
patient was diagnosed with MM/lambda light chain 
disease stage III of Durie-Salmon scale, III accord-
ing to ISS.
The patient qualified for first-line chemother-
apy according to VCD protocol. Treatment started 
in July 2017, bortezomib 1.3 mg/m2 on days 1, 4, 8, 
and 11; cyclophosphamide 375 g/m2 on days 1 and 8, 
dexamethasone 20 mg on days 1–4, 8–11 of a 28-day 
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cycle. At the same time, antibacterial and antiviral 
prophylaxis (sulfamethoxazole + trimethoprim, 
acyclovir) and anticoagulant therapy (clopidogrel) 
were continued.
On day 4 of the first VCD cycle, the patient 
suddenly deteriorated. The patient reported chest 
pain on the left side of her chest radiating to the 
shoulders and scapula and vomiting. In the per-
formed electrocardiography (ECG), ST depres-
sion in V5–V6 was seen, and in laboratory tests 
— cardiac troponin levels were rising. The patient 
with the suspected acute coronary syndrome 
was transferred to a cardiology department. Ulti-
mately myocardial infarction without ST elevation 
(NSTEMI, non-ST-elevated myocardial infarction) 
was diagnosed and effective angioplasty to the left 
main coronary (LM) trunk was performed with 
implantation of antiproliferative DES.
After stabilization of the patient’s clinical sta-
tus, haematological consultations took place again 
on day 14 after the procedure. It was decided to 
continue VCD chemotherapy with a reduced dose 
of dexamethasone 8 mg administered orally (p.o.) 
on days 1–4 and 8–11. After completing the 1st 
cycle of treatment PR was achieved, a decrease 
in FLC concentration lambda to 2581.22 mg/L 
(~53.3%) was seen. During treatment periodically 
anaemia was observed, requiring RBCC transfusion 
(once/2 months) and grade 2 polyneuropathy ac-
cording to the NCI CTCAE criteria. The renal func-
tion parameters stabilized (eGFR ~15–20 mL/min) 
with preserved diuresis, without electrolyte im-
balances. The patient did not require dialysis. She 
received 8 VCD cycles in total. The treatment 
was completed in June 2018, VGPR was obtained 
with a reduction in lambda FLC concentration to 
73.6 mg/L (~98.6%).
Disease relapse occurred shortly, 4 months after 
the end of treatment there was a 3-fold increase in 
the concentration of lambda FLC — 238.8 mg/L. 
Moderate anaemia was observed in control laboratory 
tests (Hb 8–9 g/dL) and features of chronic severe 
renal impairment (eGFR ~15–20 mL/min). The pa-
tient did not complain of any significant symptoms. 
Performance status was 2 according to the ECOG 
scale. Second-line chemotherapy IRd was started 
in October 2018 with reduced doses due to comor-
bidities. Doses administered: ixazomib 3 mg on days 
1, 8, and 15; lenalidomide 5 mg on days 1–21; 
dexamethasone 8 mg on days 1, 8, 15 and 22. 
Antibacterial and antiviral prophylaxis was given 
and thromboprophylaxis (acetylsalicylic acid) was 
continued. During treatment recurrent urinary 
tract infections were observed, pneumonia requir-
ing hospitalization and anaemia requiring RBCC 
transfusion on average once every 2 months. 
Deterioration of kidney function or cardiovascular 
status are not observed. Diuresis was preserved, 
no electrolyte imbalances were observed, eGFR 
was about 20 mL/min, in control echocardiography, 
left ventricular ejection fraction (LVEF) was around 
58%. From cycle 6, VGPR is maintained with FLC 
reduction not less than 90%. So far, the patient 
has received 18 cycles of IRd chemotherapy. The 
treatment continues.
Case 4
A 55-year-old man with refractory plasma cell  
myeloma followed by another autologous  
haematopoietic stem cell transplantation (del17p)
A 49-year-old man was admitted to the He-
matology Department of Bialystok University 
Hospital in October 2011, without a previous his-
tory of chronic illnesses, for diagnostics towards 
MM. On admission, the patient reported bone 
pain, especially in the lumbosacral spine, drench-
ing sweats and general weakness. Objectively L/S 
spine movement limitation was present. On FBC 
and blood film no significant abnormalities were 
found apart from erythrocyte rouleaux. In bio-
chemical tests, a high concentration of total protein 
[(TP) = 12.9 g/dL] was detected with the peak of 
paraprotein in the gamma globulin fraction. On se-
rum immunofixation two monoclonal protein frac-
tions (bands) were found: 1) IgG kappa 5.78 g/dL 
and 2) IgG kappa 0.32 g/dL. Calcium and serum 
creatinine concentration remained normal and 
beta2-microglobulin was 10.2 mg/L. Bone marrow 
aspirate and trephine biopsy were performed; mar-
row aspirate was hypercellular with 32% plasma 
cell infiltration, while histopathological assessment 
of the trephine revealed 60% plasma cell infiltra-
tion. X-ray skeletal survey revealed generalized 
bone porosis, numerous osteolytic lesions in 
the bones of the skull vault, clavicles, scapulae, 
ribs, sternum, long bones, pelvis and vertebrae. 
Moreover, CT of the spine revealed a tumour 
formation, dimensions approximately 47 × 41 × 
× 14 mm destructing Th10 vertebral body, partially 
indenting into to the lumen of the spinal canal with 
secondary stenosis and compression fracture of the 
Th2 vertebral body with the presence of soft tissue 
mass with dimensions of 21 × 20 × 11 mm with slight 
spinal canal stenosis as well as a pathological mass 
within the L2 vertebral body on the right with dimen-
sions of 40 × 18 × 14 mm involving the arch with 
the vertebral body height compression. IgG kappa 
MM C(–) R(–) A(–) B(+) ISS stage III was diagnosed.
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As initial treatment, two plasmapheresis 
(plasma exchange) procedures were performed 
and then systemic chemotherapy along with stand-
ard supportive and prophylactic treatment were 
started. From October 2011 to April 2012 one CD 
(cyclophosphamide, dexamethasone) course and 
four CTD (cyclophosphamide, thalidomide, dexa-
methasone) courses were administered. Thereaf-
ter, treatment was stopped due to critical ischaemia 
of the left lower limb during arterial embolism 
resulting in supracondylar limb amputation in 
April 2012. In August 2012, the disease status 
was assessed, and the patient remained in partial 
response. Chemotherapy according to CTD was 
continued; two further consecutive courses were 
given achieving a very good partial response. Ad-
ditionally, the patient underwent two vertebroplas-
ties of the lumbar vertebrae. As part of treatment 
consolidation, high-dose chemotherapy was ad-
ministered followed by autologous haematopoietic 
stem cell transplantation (auto-SCT, autologous 
stem cell transplantation) in a tandem sequence 
[April 2013 after conditioning with total bone mar-
row irradiation (TMI, total body irradiation) and 
August 2013 after conditioning with high doses of 
melphalan (HD-Mel, high-dose melphalan)]. After 
administered treatment, the patient maintained 
VGPR. For the next 4.5 years, the patient was 
under outpatient clinic follow-up.
The first disease relapse occurred in October 
2017: there was an increase in monoclonal protein 
level to 3.7 g/dL, there was bone marrow infiltra-
tion on trephine biopsy up to 50% and new bone 
lytic lesions were found. VCD chemotherapy was 
administered according to standard protocol with 
supportive treatment. The therapy was compli-
cated by worsening polyneuropathy and respiratory 
tract infections, which led to treatment interrup-
tions. In February 2018, on the reassessment of 
the disease status after four VCD courses — the 
stable disease was noted with the presence of M 
protein concentration 2.7 g/dL and with persistent 
plasma cell infiltration of approximately 25% on his-
topathological examination. In cytogenetic studies, 
deletion 17p was found. IRd therapy was initiated 
according to the standard protocol: ixazomib 4 mg on 
days 1, 8, and 15 + lenalidomide 25 mg for 21 days 
and dexamethasone 40 mg on days 1, 8, 15 and 22.
In April 2019, the patient had completed 14 
IRd courses. Disease status reassessment revealed 
partial response to treatment with reduction of 
plasma cell infiltration to less than 10% on trephine 
biopsy. The patient qualified for another autolo-
gous transplantation. In October 2019, the patient 
underwent mobilization with intermediate doses 
of cytosine arabinoside (ID-Ara-C, intermediate 
Ara-C), as a result of which haematopoietic stem 
cells were harvested. In December 2019, third 
high-dose chemotherapy followed by auto-SCT was 
carried out. As a treatment result, the patient has 
achieved a continued partial response (10 months 
from auto-SCT). During that treatment, no more 
severe than grade II according to CTCAE compli-
cations were noted, treatment tolerance was fully 
satisfactory.
Case 5
A 55-year-old female with relapsed plasma cell  
myeloma after autologous hematopoietic stem cell 
transplantation, with planned subsequent allogeneic 
hematopoietic stem cell transplantation [t(4;14)  
and chromosome 11 trisomy]
In January 2015, a 55-year-old female patient 
was diagnosed with MM based on the histopatho-
logical assessment of material taken during the 
treatment of pathological neck fracture of the 
femur. Mobilization was carried out after four cy-
cles of VTD treatment and haematopoietic stem 
cells collected in Lodz centre. After another two 
VTD cycles, the patient underwent treatment with 
a transplant. Disease status before the first trans-
plantation [MEL-200 (melphalan 200 mg/m2) — 
30/11/2015] a very good partial response, complete 
response before the second transplantation [MEL-
-140 (melphalan 140 mg/m2) — 11/04/2016]. Then 
maintenance treatment with thalidomide was con-
tinued for 6 months (finished in December 2016).
In January 2019, the patient developed severe 
bone pain. Immunohistochemical assessment of 
trephine biopsy confirmed disease progression. 
From February 2019, treatment with IRd was ad-
ministered with very good tolerance, improvement 
of general condition and improvement of bone pain. 
The patient has received 20 cycles of IRd treat-
ment so far which has been tolerated. Bone pain 
subsided. A complete response has been achieved. 
Due to past tandem transplantation, high cytoge-
netic risk [t(4;14) and chromosome 11 trisomy] 
and short first remission, the patient was qualified 
for allogeneic bone marrow transplantation (allo-
-SCT, allogeneic stem cell transplantation) in the 
Institute of Oncology in Gliwice. On 2nd September 
2020, the patient received myeloablative chemo-
therapy according to MEL-140 protocol.
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Case 6
A 55-year-old male with second plasma cell myeloma 
relapse, after two autologous haematopoietic stem 
cell transplantations, with an aggressive course  
of the disease
A 48-year-old man reported to the Oncology 
Centre — Institute (CO-I, Centrum Onkologii — 
Instytut) in Warsaw in 2010 with a several-month 
history of severe bone pain and suspicion of osteo-
lytic lesions in the spine vertebrae based on X-ray 
examination of the thoracolumbar spine carried out 
in primary care. Diagnostics carried out in CO-I 
revealed: disseminated osteolytic lesions, most 
severe in the thoracic and lumbar spine, sacrum, 
pelvis and sternum, high protein M concentration 
in serum (32 g/L) in IgG class with kappa light 
chains, anaemia with Hb concentration of 10.2 g/dL 
and 35% bone marrow infiltration by plasma cells. 
MM in stage IIIA according to the Durie-Salmon 
scale and IIIA according to the ISS was diagnosed.
The patient qualified for induction treatment 
according to the CTD regimen with the transplant 
procedure as a plan. The patient received 8 CTD 
courses, yielding VGPR. During the induction 
treatment, successful mobilization and collection 
of stem cells with high doses of cyclophosphamide 
and granulocyte colony-stimulating factor (G-CSF) 
were carried out. Simultaneously with induction 
treatment supportive treatment with bisphospho-
nates was given, and after stem cell harvesting the 
patient underwent irradiation to the most destruc-
tive lesions of the skeleton, i.e., to Th10–S5 area. 
In 2011, after myeloablative therapy MEL-200, 
auto-SCT was performed, 2.7 × 106 CD34/kg body 
weight were administered. Due to persistent VGPR 
after auto-SCT, the patient qualified for thalidomide 
maintenance treatment, which was given until dis-
ease progression, i.e., for 3 years (2011–2014). In 
2014, in the absence of clinical symptoms, based 
on routine control blood and urine tests, PD was 
diagnosed. The serum concentration of TP was 
increased as well as the concentration of FLC was 
significantly increased in serum with an abnormal 
FLC ratio and presence of Bence-Jones protein 
in the urine (initially absent). Further diagnostics 
showed again 30% marrow involvement by plasma 
cells and the presence of new osteolytic lesions in 
the skull, ribs and bones of the limbs. At that time, 
no adverse cytogenetic prognostic factors were 
found. The patient was qualified for a second-line 
systemic treatment according to the PAD regi-
men (bortezomib, doxorubicin, dexamethasone) 
which turned out to be ineffective — after four 
courses no satisfactory response was achieved 
(less than PR). Additionally, the patient developed 
side effects: grade 3 neutropenia and grade 3 pe-
ripheral polyneuropathy (therefore, the patient re-
quired G-CSF and bortezomib dose reduction). As 
a third-line treatment, individual chemotherapy CE 
(cyclophosphamide, etoposide) was given. After 
six CE courses, PR was obtained, again mobiliza-
tion and collection of stem cells with high doses 
of cyclophosphamide and G-CSF (plerixafor) were 
performed. In 2015, a second transplant procedure 
was performed, 4.1 × 106 CD34/kg body weight 
were administered. Again, on disease response 
assessment to auto-SCT, VGPR was noted which 
lasted for 2 years. In 2017, a second disease pro-
gression occurred; a massive concentration of M 
protein was present in serum (IgG 6000 mg/dL), 
high kappa FLC concentration in both serum and 
urine, anaemia and thrombocytopenia. In Septem-
ber 2017, the patient started fourth line systemic 
treatment with lenalidomide, ixazomib, and dexa-
methasone. After 12 months of therapy, a very good 
effect of treatment was achieved: normalization of 
TP concentration, a significant decrease in IgG con-
centration and normalization of serum FLC ratio. 
Blood counts improved significantly — no thrombo-
cytopenia or anaemia. In the latest protein control 
studies in September 2018, M protein IgG kappa 
in serum was sustained and Bence-Jones protein 
in low concentrations (response was assessed as 
VGPR). The patient continues treatment with good 
haematological tolerance, but dexamethasone dose 
reduction was required due to undesirable signs of 
steroid therapy. A very good laboratory response 
to treatment is shown in Figures 1 and 2.
Discussion
Treatment of patients with RRMM in everyday 
clinical practice is challenging. Despite enormous 
progress linked to the implementation of PI and 
ImiD, MM remains an incurable disease. Nowadays 
the basis for the therapy of this disease entity are 
modern two-, three- and even four-drug protocols 
consisting of ImiD, PI, corticosteroids, monoclonal 
antibodies and classical chemotherapeutic agents 
[9, 10].
According to the international prognostic scor-
ing classification, the 5-year survival rate in the R- 
-ISS stage equal to 1 is 82%, in the R-ISS stage 
equal to 2 — 62%, while in the R-ISS stage equal 
to 3 — only 40%. Factors determining worse 
prognosis in R-ISS stage equal to 3 are beta2-
microglobulin concentration above 5.5 mg/L, in-
creased activity of serum lactate dehydrogenase 
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(LDH) and/or presence of adverse cytogenetic 
aberrations, such as del17p, t(4;14), t(14;16) [11].
High-risk cytogenetic aberrations in patients 
with MM are of particular therapeutic challenge. 
Chromosomal aberrations in neoplastic cells lead 
to the development of resistance, which translates 
into a reduction of complete and deep response 
rates to treatment and shortening the time to PFS 
and overall survival (OS) [12]. Due to unsatisfac-
tory treatment results of high-risk MM new drugs 
Figure 1. Reduction of M-protein peak in serum protein electrophoresis as a result of treatment with IRd (ixazomib, 
lenalidomide, dexamethasone). The arrow indicates the start time of IRd treatment
Figure 2. Dynamics of changes in the value of lambda free light chains (FLC) in serum during treatment according to 
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and regimens are being sought with higher efficacy 
and not increased toxicity at the same time [13].
Proteasome inhibitors are a group of drugs 
that bind to the proteasomal complex, leading to 
blockage of chymotrypsin-like activity, which in 
turn causes the accumulation of abnormal proteins 
in the cell and the activation of apoptosis cascade 
[14]. The first PI widely used in anti-cancer therapy 
is bortezomib, which rapidly and reversibly in-
hibits the activity of the proteasome, resulting in 
decreased expression of proteins responsible for 
survival, growth and proliferation of neoplastic 
cells. The drug is administered as an intravenous 
or subcutaneous injection. The side effect profile 
is predominately haematological toxicity and poly-
neuropathy and infections [15]. Second generation 
PIs are of much lower risk of neurotoxicity; irrevers-
ible PI carfilzomib and reversible PI ixazomib [16].
Used in the presented cases ixazomib within 
the IRd regimen is the first oral PI approved for the 
treatment of MM. The drug binds preferentially to 
the beta 5 subunit of the proteasome, resulting in 
induction of apoptosis activation in myeloma cells. 
Registration indications include treatment, in com-
bination with lenalidomide and dexamethasone, in 
adult patients with MM who previously received 
at least one line of therapy [15]. Particularly 
noteworthy is the fact that in the TOURMALINE-
-MM1 registration study an increase in PFS from 
9.7 to 21.4 months was observed in the group of 
patients with high-risk myeloma associated with 
cytogenetic aberrations del17p, t(4;14), t(14;16). 
Also, no additional toxicity was observed with the 
addition of ixazomib to Rd therapy [8]. Ixazomib 
has been also studied in subpopulations of patients 
with unfavourable cytogenetic changes and PFS 
prolongation was demonstrated in different patient 
groups: with del(17p) [hazard ratio (HR) 0.596, 95% 
confidence interval (CI): 0.286–1.243], amplifica-
tion 1q21 (HR 0.781, 95% CI: 0.492–1.240) and 
the group of patients with coexistence of adverse 
cytogenetic changes and/or 1q21 amplification 
(HR 0.664, 95% CI: 0.474–0.928) [17].
Both, the current clinical recommendations 
of the Polish Myeloma Group and the American 
National Comprehensive Cancer Network (NCCN) 
indicate ixazomib in combination with lenalidomide 
and dexamethasone for the treatment of MM pa-
tients who received at least one line of treatment 
[18, 19]. It is worth emphasizing that in the case of 
combination therapy with ixazomib, lenalidomide 
and dexamethasone as well as regimens containing 
carfilzomib improvement of OS of patients with re-
lapsed or refractory MM has been shown [20–22].
The cases presented in this paper illustrate 
good treatment outcomes in patients burdened 
with unfavourable prognostic factors, including the 
presence of high-risk cytogenetic aberrations. The 
patients responded to treatment, which in some 
cases enabled the use of high-dose chemotherapy 
followed by autologous haematopoietic stem cell 
transplantation. Moreover, considering multiple 
comorbidities and the distance from the reference 
centres, the use of oral therapy with ixazomib can 
lead to a significant improvement of patient quality 
of life and reduce the risk of treatment discontinu-
ation in clinical practice for reasons unrelated to 
progression or treatment toxicity [23].
Clonal evolution related to the course of my-
eloma treatment leads to the selection of resistant 
clones leading to a loss of response to therapy. Ad-
ministered therapies result in the removal of clones 
sensitive to drugs while promoting the progression 
of aggressive clones [24]. Therefore, the use of 
multi-drug therapies with the highest possible ef-
fectiveness against different clones or subclones 
of myeloma cells is highly beneficial. Usually, new 
drugs are used in combination with traditional cy-
totoxic medications, which allows obtaining a good 
response to treatment and prolongation of PFS in 
most patients with RRMM [25].
In summary, an oral well-tolerated regimen 
containing ixazomib, lenalidomide and dexametha-
sone represent an important therapeutic option 
for all patients with relapsed or refractory MM, 
particularly for high-risk patients with unfavour-
able cytogenetic findings.
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